Corrigendum to “Monitoring unbound warfarin in drug combination therapy by pharmacokinetics and fluorospectrometry” Chinese Herbal Medicines 11 (2019) 92–97 (Chinese Herbal Medicines (2019) 11(1) (92–97), (S167463841830145X), (10.1016/j.chmed.2018.10.002)) / 中草药·英文版

When this paper was first published the following ethical statement was omitted in error: Animal experiments were conducted in accordance with the guidelines of Laboratory Animal Ethics Committee of Tianjin University of Traditional Chinese Medicine (TCM-LAEC2019071). The authors would like to apologise for any inconvenience caused. DOI of original article: https://doi.org/10.1016/j.chmed.2018.10.002

Monitoring unbound warfarin in drug combination therapy by pharmacokinetics and fluorospectrometry / 中草药·英文版

Objective: Monitoring the unbound drug concentration in blood in combination therapy is necessary, because its concentration determines the efficacy of drug therapy. This study was designed to explore the effect of Dan Hong Injection (DHI) on the unbound warfarin using two approaches including an in vivo pharmacokinetic and in vitro fluorescence studies. Methods: The effect of DHI on the pharmacokinetic properties of the unbound warfarin was investigated by a microdialysis sampling method coupled with LC–MS/MS. The effect of DHI and salvianolic acid B (SaB) on warfarin binding with bovine serum albumin (BSA) was conducted by fluorescence spectrometry. Results: The AUC0-tn of warfarin with DHI group was higher than that of warfarin alone group. The result showed that DHI could increase the concentration of unbound warfarin in rat blood, which may be due to the competition between warfarin and DHI as well as its components binding to serum albumin. The competition process was demonstrated by fluorescence study. Conclusion: Combination therapy of DHI with warfarin could enhance the release profile of warfarin from serum protein.